Clinical trial
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
NCT00398814 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00398814 |
|---|---|
| Title | Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers |
| Official title | An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sorafenib for Patients With Advanced Cancers |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Renal Cancer, Tumors |
| Intervention type | Drug |
| Interventions | Perifosine, Sorafenib |
| Enrollment | 30 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Nov 14, 2006 |
| Last update posted | Feb 19, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: